This study, together with other preclinical and clinical evidence, demonstrated that targeting the CXCL12/CXCR4/CXCR7 axis could be a promising and powerful therapeutic strategy in thyroid cancers [62,63,64]. This evidence concerns the gene CXCR4 and thyroid cancer.